Development of New Treatments through Clinical Research, Clinical Trials and Joint Research with Universities
First written in FY2016. 18 of 30 entries say "Restated". Latest entry: FY2027-H1.
3 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「During the interim consolidated accounting period, the Group’s research and development activities focused on the development of products for sale and DX development for hospital facility management. Total research and development expenses were ¥24.116 million.」
The scope of research and development was expanded to include DX development for hospital facility management, and ¥24.116 million was recorded as research and development expenses for the interim consolidated accounting period. - FY2026Update to R&D expenditureAnnual report
「Research and development expenditure for veterinary medical and health management devices for home care totaled ¥11,396 thousand during the current fiscal year.」
The Group continued research and development of veterinary medical and health management devices for home care and disclosed research and development expenditure of ¥11,396 thousand for the current consolidated fiscal year. - FY2026-H1Update to R&D expenditureAnnual report
「The Group's research and development activities during the current interim consolidated accounting period were aimed at researching and developing products for sale. Total research and development expenditure was ¥364 thousand.」
The Group continued research and development activities aimed at developing products for sale and disclosed research and development expenditure of ¥364 thousand for the current interim consolidated accounting period. - FY2024Update to R&D expenditureAnnual report
「(3) Animal health management devices Research and development expenditure for the animal health management device "Oxygen House" totaled ¥7,547 thousand during the current fiscal year.」
The Group continued research and development of the animal health management device "Oxygen House" and disclosed research and development expenditure of ¥7,547 thousand for the current consolidated fiscal year. - FY2024-Q3Update to R&D expenditureAnnual report
「The Group's research and development activities during the first nine months of the current consolidated cumulative period were aimed at researching and developing products for sale. Total research and development expenditure was ¥5,344 thousand.」
The Group continued research and development activities aimed at developing products for sale and disclosed research and development expenditure of ¥5,344 thousand for the first nine months of the current consolidated cumulative period. - FY2024-Q2Update to R&D expenditureAnnual report
「The Group's research and development activities during the first half of the current consolidated cumulative period were aimed at researching and developing products for sale. Total research and development expenditure was ¥757 thousand.」
The Group continued research and development activities aimed at developing products for sale and disclosed research and development expenditure of ¥757 thousand for the first half of the current consolidated cumulative period. - FY2023AdvancedAnnual report
「The Group will also actively pursue joint research with universities and other institutions in both clinical and non-clinical fields, thereby contributing to the advancement of animal healthcare.」
The Group has indicated a policy of actively expanding joint research with universities and other institutions in both clinical and non-clinical fields. It also recorded ¥7,992 thousand in research and development expenditure for the animal health management device "Oxygen House." - FY2023-Q2RestatedAnnual report
「The Group's research and development activities during the first half of the current consolidated cumulative period were aimed at researching and developing products for sale. Total research and development expenditure was ¥1,652 thousand.」
The Group continued research and development activities aimed at developing products for sale, with research and development expenditure for the first half of the current consolidated cumulative period totaling ¥1,652 thousand. - FY2023-Q1AdvancedAnnual report
「The Group's research and development activities during the first quarter of the current consolidated cumulative period were aimed at researching and developing products for sale. Total research and development expenditure was ¥1,430 thousand.」
The Group continued research and development activities aimed at developing products for sale and recorded research and development expenditure of ¥1,430 thousand during the quarter. - FY2022-Q3RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the nine-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the nine-month cumulative consolidated period.」
The Group reports that there was no research and development expenditure during the first nine months of the current consolidated cumulative period and no material change in the status of its research and development activities. - FY2022-Q2RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the six-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the six-month cumulative consolidated period.」
The Group reports that there was no research and development expenditure during the quarter and no material change in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「There was no research and development expenditure for the first quarter of the current consolidated cumulative period. In addition, there were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The Group reports that there was no research and development expenditure and no material change in the status of its research and development activities. - FY2021RestatedAnnual report
「The Group undertakes contract development for companies engaged in animal healthcare. In the research and development of pharmaceuticals, feed and medical devices, we contribute broadly to society by undertaking clinical trial work required for the approval of pharmaceuticals and medical devices developed by various companies, drawing on our extensive clinical case experience. We also conduct genetic analyses of a large number of cancer cases and work to accumulate the data required to develop new drugs.」
The Group continues to undertake clinical trials, conduct genetic analyses of cancer cases and contribute to the development of new drugs and medical devices using its clinical case experience. - FY2021-Q3RestatedAnnual report
「There was no research and development expenditure for the first nine months of the current consolidated cumulative period. In addition, there were no material changes in the status of the Group's research and development activities during the first nine months of the current consolidated cumulative period.」
The document states that there were no research and development activity expenses during the quarter and no material changes in the status of research and development activities. - FY2021-Q2RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the six-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the six-month cumulative consolidated period.」
The Group reports that there was no research and development expenditure and no material change in the status of its research and development activities. - FY2021-Q1RestatedAnnual report
「There was no research and development expenditure for the first quarter of the current consolidated cumulative period. In addition, there were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The Group reports that there was no research and development expenditure and no material change in the status of its research and development activities. - FY2020AdvancedAnnual report
「Our group promoted joint research with universities and research institutions to use the activity monitor "Plus Cycle" in advancing new technologies in the animal healthcare field. However, as the business shifted to a phase centered on sales activities during the consolidated fiscal year, there were no research and development expenses.」
The company stated that the activity monitor "Plus Cycle" had moved from joint research with universities and research institutions to a business phase centered on sales activities. - FY2020-Q3RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the nine-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the nine-month cumulative consolidated period.」
The document states that there were no research and development activity expenses during the quarter and no material changes in the status of research and development activities. - FY2020-Q2RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the six-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the six-month cumulative consolidated period.」
The document states that there were no research and development activity expenses during the quarter and no material changes in the status of research and development activities. - FY2020-Q1RestatedAnnual report
「No applicable matters.」
The company stated that there were no applicable matters concerning research and development activities during the three-month cumulative consolidated period. - FY2019RestatedAnnual report
「Our group conducts contract development for companies involved in animal healthcare. In research and development relating to pharmaceuticals, feed and medical equipment, we contribute broadly to society by undertaking the clinical trials required for regulatory approval of pharmaceuticals and medical equipment developed by various companies, drawing on our extensive clinical case experience. We also conduct genetic analysis of numerous cancer cases and work to accumulate data required for the development of new drugs. There were no research and development expenses for contract development during the consolidated fiscal year. In addition, we recorded ¥100,000 as research and development expenses for maintenance fees for software required for academic research.」
The company continued contract clinical trials, genetic analysis of cancer cases and maintenance of software for academic research. - FY2019-Q3RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the nine-month cumulative consolidated period was ¥2.1 million. There were no material changes in the status of the group's research and development activities during the nine-month cumulative consolidated period.」
Research and development expenses for the nine-month cumulative consolidated period were ¥100,000, and the company stated that there were no material changes in the status of its research and development activities. - FY2019-Q2RestatedAnnual report
「There was no spending on research and development activities by the group as a whole during the six-month cumulative consolidated period. There were no material changes in the status of the group's research and development activities during the six-month cumulative consolidated period.」
The document states that there were no research and development activity expenses during the quarter and no material changes in the status of research and development activities. - FY2019-Q1No quarterly research and development activityAnnual report
「No applicable matters.」
The company stated that there were no applicable matters concerning research and development activities during the three-month cumulative consolidated period. - FY2018AdvancedAnnual report
「Our group conducts contract development for companies involved in animal healthcare. In research and development relating to pharmaceuticals, feed and medical equipment, we contribute broadly to society by undertaking the clinical trials required for regulatory approval of pharmaceuticals and medical equipment developed by various companies, drawing on our extensive clinical case experience. We also conduct genetic analysis of numerous cancer cases and work to accumulate data required for the development of new drugs. There were no research and development expenses for contract development during the consolidated fiscal year. In addition, we recorded ¥2.5 million as research and development expenses for the purchase of software required to use an MRI system for academic research.」
The company continued contract clinical trials and genetic analysis of cancer cases, and recorded ¥2.5 million in research and development expenses for software purchased to use MRI for academic research. - FY2018-Q3RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the nine-month cumulative consolidated period was ¥2.1 million. There were no material changes in the group's research and development activities during the nine-month cumulative consolidated period.」
¥2.1 million was recorded for research and development activities, and the company stated that there were no material changes in the status of those activities. - FY2018-Q2RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the six-month cumulative consolidated period was ¥2.1 million. There were no material changes in the group's research and development activities during the six-month cumulative consolidated period.」
¥2.1 million was recorded for research and development activities, and the company stated that there were no material changes in the status of those activities. - FY2017RestatedAnnual report
「In clinical research, in addition to contract clinical trials for veterinary drugs, diagnostic agents and medical equipment, the company conducted joint research with universities on disease mechanisms and pathological analysis in the fields of gastroenterology, neurology, cardiovascular medicine and oncology, contributing to the future development and introduction in Japan of cutting-edge medical treatments.」
The company continued contract clinical trials and joint research with universities, and also identified cardiovascular medicine and other fields among its research areas. - FY2017-Q3RestatedAnnual report
「The amount spent on research and development activities by the group as a whole during the nine-month cumulative consolidated period was ¥4.543 million. There were no material changes in the group's research and development activities during the nine-month cumulative consolidated period.」
Research and development activities amounted to ¥4.543 million, and the company stated that there were no material changes in the status of those activities. - FY2016First statedAnnual report
「In clinical research, in addition to contract clinical trials for veterinary drugs and medical equipment in the oncology field, the company conducted joint research with universities in the fields of gastroenterology, neurology and oncology, contributing to the future development and introduction in Japan of new cutting-edge medical treatments.」
A foundation for developing new drugs and medical treatments through contract clinical trials, joint research with universities and genetic analysis.